The Clinical Significance Of Serum High-sensitivity C-reactive Protein Combined With Prostate Specific Antigen For Prostate Biopsy

Backfround:Serum prostate-specific antigen(PSA),as one of the biological indicators for the diagnosis of prostate cancer,has been found and widely used for many years.The normal value is 0-4ng/ml,while a PSA value greater than 10ng/ml greatly increases the possibility of prostate cancer.clinical practice,the PSA value of most patients was greater than 4ng/ml at the first visit,and the biopsy results of prostate biopsy were negative in a considerable number of patients.According to relevant domestic and foreign scholars,in patients with PSA greater than 20ng/ml,the positive rate of prostate biopsy can be close to 50%,while in patients with PSA of 4-20ng/ml,the positive rate of prostate biopsy drops to about 19%,and in the "gray range" of 4-10ng/ml,the positive rate of prostate biopsy is even lower.In recent years,domestic and foreign scholars have applied f/t PSA,PSAD combined with PSA to improve the positive rate of prostate biopsy,but with little effect.This paper aims to find a new biological indicator to improve the positive rate of prostate biopsy in such patients.Serum high-sensitivity c-reactive protein(hs-CRP)as a produced in the liver,rise in systemic inflammatory response of an acute phase plasma protein,has been reported at home and abroad has increased in many diseases,including cardiovascular disease,autoimmune disorders and lung cancer,colorectal cancer and urinary tract cancer and other cancers,its normal range from 0 to 3 mg/l.Objective: To verify the clinical significance of the combination of hs-CRP> 3mg/l in predicting the positive rate of prostate biopsy in the prospective prostate biopsy group whose PSA value is greater than 4 ng/ml.Methods: The consistency between PSA > 4ng/ml combined with hs-crp> 3mg/l and the final positive rate of prostate needle biopsy was tested by kappa consistency test.The chi-square test was used to compare the accuracy of hs-CRP combined with PSA and PSA alone in predicting the positive rate of prostate puncture biopsy.According to the risk group divided by PSA value,hs-CRP was studied to determine whether there was a difference in predicting the final positive rate of prostate puncture biopsy in each group.Finally,for the "gray range" of PSA between 4and 10ng/ml,hs-CRP was compared with PSA alone to predict the positive rate of prostate puncture biopsy.Results:hs-CRP> 3mg/l combined with PSA predicted the positive rate of prostate biopsy and the final pathological positive rate of prostate biopsy.The accuracy of hs-CRP combined with PSA in predicting the positive rate of prostate biopsy was 77.3%,and that of PSA > 4ng/ml alone was 32.87%(? 2=14.67,P<0.05).hs-CRP combined with low risk,medium risk and high risk PSA,the accuracy of positive prostate biopsy was 84.54%,79.03% and 89.47%,respectively(? 2=0.287,P > 0.05).The accuracy of hs-CRP combined with psa4-10 ng /ml in predicting the positive rate of puncture biopsy was 76.53%,and that of PSA(4-10ng/ml)alone was 30.61%(?2=21.53,P<0.05),the difference was statistically significant.Conclusions:hs-CRP combined with PSA has clinical significance in predicting the positive rate of prostate biopsy.compared with PSA alone,PSA combined with hs-CRP has higher accuracy in predicting the positive rate of prostate puncture biopsy.The combination of hs-CRP and PSA had no significant difference in predicting the final positive rate of prostate biopsy in each group.In the "gray range" of PSA value of 4-10 ng/ml,PSA combined with hs-CRP can improve the positive rate of final prostate puncture biopsy.